株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尋常性座瘡 : パイプライン製品の分析

Acne Vulgaris - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232807
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。
Back to Top
尋常性座瘡 : パイプライン製品の分析 Acne Vulgaris - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 182 Pages
概要

尋常性座瘡とは、顔および上躯幹の毛包脂腺小胞の異常であり、吹き出ものが炎症を起こし、膿疱、結節、嚢胞などになると、痛みを持つ場合もあります。青年期、ヘアジェル、油性の化粧品、ヘルメットのストラップの摩擦などスポーツ用品、皮膚の閉塞などが素因となり、抗生物質で治療します。

当レポートでは、世界における尋常性座瘡治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

尋常性座瘡の概要

治療薬の開発

  • 尋常性座瘡向けパイプライン製品:概要
  • 尋常性座瘡:開発中の治療薬:企業別
  • 尋常性座瘡:開発中の治療薬:大学・研究機関別
  • 尋常性座瘡:開発中の製品:企業別
  • 尋常性座瘡:開発中の製品:大学・研究機関別

尋常性座瘡:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

尋常性座瘡:治療薬開発に従事している企業

  • 3SBio Inc
  • Allergan Plc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Cell Medica Ltd
  • Cellceutix Corp
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Dermira Inc
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • GlaxoSmithKline Plc
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Valeant Pharmaceuticals International Inc
  • Vectura Group Plc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc

薬剤プロファイル

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

目次
Product Code: GMDHC10391IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2018, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 20, 5, 1, 16 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acne Vulgaris - Overview
  • Acne Vulgaris - Therapeutics Development
  • Acne Vulgaris - Therapeutics Assessment
  • Acne Vulgaris - Companies Involved in Therapeutics Development
  • Acne Vulgaris - Drug Profiles
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Acne Vulgaris, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 6: Products under Development by Companies, H1 2018
  • Table 7: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 8: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 9: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 10: Products under Development by Universities/Institutes, H1 2018
  • Table 11: Number of Products by Stage and Target, H1 2018
  • Table 12: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 13: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 14: Number of Products by Stage and Route of Administration, H1 2018
  • Table 15: Number of Products by Stage and Molecule Type, H1 2018
  • Table 16: Acne Vulgaris - Pipeline by 3SBio Inc, H1 2018
  • Table 17: Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2018
  • Table 18: Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H1 2018
  • Table 19: Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2018
  • Table 20: Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2018
  • Table 21: Acne Vulgaris - Pipeline by Daewoong Co Ltd, H1 2018
  • Table 22: Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018
  • Table 23: Acne Vulgaris - Pipeline by ELORAC Inc, H1 2018
  • Table 24: Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H1 2018
  • Table 25: Acne Vulgaris - Pipeline by Galderma SA, H1 2018
  • Table 26: Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2018
  • Table 27: Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H1 2018
  • Table 28: Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
  • Table 29: Acne Vulgaris - Pipeline by LEO Pharma A/S, H1 2018
  • Table 30: Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H1 2018
  • Table 31: Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2018
  • Table 32: Acne Vulgaris - Pipeline by Novan Inc, H1 2018
  • Table 33: Acne Vulgaris - Pipeline by Novartis AG, H1 2018
  • Table 34: Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H1 2018
  • Table 35: Acne Vulgaris - Pipeline by Pfizer Inc, H1 2018
  • Table 36: Acne Vulgaris - Pipeline by Phagelux Inc, H1 2018
  • Table 37: Acne Vulgaris - Pipeline by Phosphagenics Ltd, H1 2018
  • Table 38: Acne Vulgaris - Pipeline by Photocure ASA, H1 2018
  • Table 39: Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2018
  • Table 40: Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2018
  • Table 41: Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H1 2018
  • Table 42: Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
  • Table 43: Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2018
  • Table 44: Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2018
  • Table 45: Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H1 2018
  • Table 46: Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H1 2018
  • Table 47: Acne Vulgaris - Pipeline by XBiotech Inc, H1 2018
  • Table 48: Acne Vulgaris - Dormant Projects, H1 2018
  • Table 49: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Table 50: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Table 51: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..3), H1 2018
  • Table 52: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..4), H1 2018
  • Table 53: Acne Vulgaris - Dormant Projects, H1 2018 (Contd..5), H1 2018
  • Table 54: Acne Vulgaris - Discontinued Products, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Acne Vulgaris, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products by Top 10 Targets, H1 2018
  • Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Routes of Administration, H1 2018
  • Figure 8: Number of Products by Stage and Routes of Administration, H1 2018
  • Figure 9: Number of Products by Molecule Types, H1 2018
  • Figure 10: Number of Products by Stage and Molecule Types, H1 2018
Back to Top